PenRad’s mammography information system (MIS) has been named the Category Leader in the “2012 Best in KLAS Awards: Software and Services” report for MIS technology for the fifth consecutive year by KLAS. KLAS rankings are based on product quality, ease-of-use and price, as well as customer support according to evaluations given by system users. Since KLAS began analyzing the MIS market in 2008, PenRad MIS has won the Category Leader each year consecutively.

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of beta-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.[1]

GSI Group Inc., a leading supplier of laser-based solutions, precision motion and optical technologies to global industrial, medical, electronics and scientific markets, announced that it has acquired NDS Surgical Imaging (NDS), a San Jose, Calif.-based global leader in surgical and radiology displays and related peripherals, for $82.5 million in cash, subject to customary closing adjustments.

GE Healthcare introduced an expansion of the line of Caring Magnetic Resonance (MR) Suites, built by PDC, that now includes designs specific to GE’s Extremity Optima 430s MR scanner.

DICOM Grid, a global provider of cloud-based medical image exchange solutions, recently launched its next generation clinical viewer. This latest release enables the easy access and viewing of complex medical imaging data and associated reporting from any browser-based device or iPad.

Molecular breast imaging company Gamma Medica, Inc. is expanding the capabilities of its LumaGEM Molecular Breast Imaging (MBI) System with a biopsy accessory. Gamma Medica’s technology clearly lights up tumors, even those obscured by dense breast tissue. This new LumaGUIDE hardware and software package, currently a work-in-progress, will allow physicians to precisely identify and biopsy suspicious lesions. The new procedure is quick (about half the time of an MRI-guided biopsy), easy-to-use, and streamlined.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced the completion of a study of its novel radiopharmaceutical NAV4694 as a biomarker for visual detection and quantification of cerebral ?-amyloid in diagnosing Alzheimer’s disease (AD). The study was designed and conducted by Navidea’s partner, AstraZeneca, to assess the effects of various mass amounts of AZD4694 (NAV4694) on safety and the efficacy of positron emission tomography (PET) scanning in subjects with AD and in healthy volunteers (HVs). Evaluations were completed on the effects of two mass doses of the radioligand on binding parameters and overall image quality. These endpoints are typical and important requirements of drug registration dossiers filed with regulatory authorities for approval of diagnostic agents.


The number of students entering radiography educational programs decreased in 2012, according to the latest American Society of Radiologic Technologists (ASRT) Enrollment Snapshot of Radiography, Radiation Therapy and Nuclear Medicine Technology Programs.
electronic health records, MU

The American Medical Association (AMA) submitted formal comments to the Office of the National Coordinator for Health Information Technology (ONC) on the Health IT Policy Committee’s proposal for Stage 3 of the Medicare/Medicaid meaningful use electronic health record (EHR) program requirements.

Lantheus Medical Imaging Inc. has added a low-enriched uranium (LEU) TechneLite (technetium Tc 99m Generator) generator to the its nuclear imaging product portfolio. Lantheus’ LEU TechneLite generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95 percent LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain. Lantheus’ first LEU TechneLite generator was shipped on Jan. 7, 2013.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now